SCHEMBL5233589

SCHEMBL5233589

CCOC(=O)c1ccc(OCc2ccccc2)cc1C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.63
HSP90AA1 P07900 1/20 0.63
KMT2A Q03164 1/20 0.63
MAOB P27338 2/20 0.61
LMNA P02545 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NMT1 P30419 4/20 0.56
NMT2 O60551 1/20 0.56
GABRA1 P14867 1/20 0.56
GABRG2 P18507 1/20 0.56
GABRB3 P28472 1/20 0.56
GABRA5 P31644 1/20 0.56
GABRA3 P34903 1/20 0.56
GABRA2 P47869 1/20 0.56
PPARG P37231 1/20 0.55
NR1H4 Q96RI1 1/20 0.54
ALDH1A1 P00352 2/20 0.54
LTB4R Q15722 1/20 0.53
LTB4R2 Q9NPC1 1/20 0.53
TSHR P16473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16269061 0.88 MAOB (0.67) MEN1HSP90AA1KMT2AMAOBLMNA
SCHEMBL11589577 0.88 MEN1 (0.65) MEN1HSP90AA1KMT2AMAOBLMNA
SCHEMBL22438915 0.88 MEN1 (0.65) MEN1HSP90AA1KMT2AMAOBLMNA
SCHEMBL10468397 0.86 MEN1 (0.63) MEN1HSP90AA1KMT2AMAOBLMNA
SCHEMBL4816779 0.86 MEN1 (0.63) MEN1HSP90AA1KMT2AMAOBLMNA
SCHEMBL1488776 0.86 MEN1 (0.63) MEN1HSP90AA1KMT2AMAOBLMNA
SCHEMBL22692220 0.86 MAOB (0.59) MEN1KMT2AMAOBLMNAALDH1A1
SCHEMBL7161222 0.85 MAOB (0.65) MEN1KMT2AMAOBLMNAALDH1A1
SCHEMBL23796975 0.85 MEN1 (0.59) MEN1HSP90AA1KMT2AMAOBLMNA
SCHEMBL10469361 0.85 MEN1 (0.62) MEN1HSP90AA1KMT2AMAOBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
CN-1500080-A Fused heterocyclic compounds ����ҩƷ��ҵ��ʽ���� 2004-05-26 CN disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed
EP-1355886-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2003-10-29 EP disclosed
WO-2002062764-A9 FUSED HETEROCYCLIC COMPOUNDS TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2002-10-10 WO disclosed
WO-2002062764-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 MEN1 1445/4885HSP90AA1 3396/4885KMT2A 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.